- Open Access
Explore the distribution of (rs35742686, rs3892097 and rs1065852) genetic polymorphisms of cytochrome P4502D6 gene in the Moroccan population
Egyptian Journal of Medical Human Genetics volume 23, Article number: 153 (2022)
The CYP2D6 gene encodes a crucial enzyme involved in the metabolic pathways of many commonly used drugs. It is a highly polymorphic gene inducing an interethnic and interindividual variability in disease susceptibility and treatment response. The aim of this study is to evaluate the frequency of the three CYP2D6 most investigated alleles (CYP2D6*3, CYP2D6*4, and CYP2D6*10 alleles) in Morocco compared to other populations.
This study enrolled 321 healthy Moroccan subjects. CYP2D6 genotypes and allele frequencies were assessed using a restriction fragment length polymorphism–polymerase chain reaction genotyping method. The Principal Component Analysis (PCA) and dendrogram were conducted to evaluate genetic proximity between Moroccans and other populations depending on CYP2D6 allele frequencies.
According to the current study, the results observed the homozygous wild type of the three studied SNPs were predominant among the Moroccan population, while 1.4% of Moroccans carried the CYP2D6*4 allele responsible for a Poor Metabolizer phenotype and associated with low enzyme activity which may induce a treatment failure. The PCA and cluster dendrogram tools revealed genetic proximity between Moroccans and Mediterranean, European and African populations, versus a distancing from Asian populations.
The distribution of CYP2D6 polymorphisms within Morocco follows the patterns generally found among the Mediterranean, European and African populations. Furthermore, these results will help to lay a basis for clinical studies, aimed to introduce and optimize a personalized therapy in the Moroccan population.
Cytochrome P450 2D6 (CYP2D6) enzyme is a key member of the Cytochrome P450 superfamily implicated in detoxification and metabolism of a wide range of endogenous and exogenous compounds, as well as in hormone synthesis and breakdown [1, 2]. CYP2D6 is one of the most extensively investigated enzymes owing to its role in the metabolism of 25% of all clinically used drugs, including various antidepressants, β-blockers, several opioid analgesics and anticancer drugs . CYP2D6 is a highly polymorphic gene located on chromosome 22q13.1 [4, 5]. So far, more than a hundred CYP2D6 allelic variants were reported in the Pharmacogene Variation Consortium (https://www.pharmvar.org/). Genetic polymorphisms are responsible for null, decreased, normal or increased functions, altering enzyme activity among individuals and populations and consequently affecting pharmacological therapy outcomes [6,7,8]. Several metabolic phenotypes have been reported depending on CYP2D6 genotypes. Actually, individuals with two non-functional alleles are considered poor metabolizers (PM) unable to metabolize drugs, while carrying at least one increased function allele confers an ultrarapid metabolizer phenotype (URM) with increased CYP2D6 activity . Otherwise, individuals with at least one decreased function allele are supplying reduced CYP2D6 activity and are considered as intermediate metabolizers (IM). Normal metabolizers (NM) are individuals with wild type alleles and normal CYP2D6 enzyme activity. Clinical studies reported an association between abnormal metabolizer phenotypes and risk of undergoing dose-related adverse events or lack of treatment efficiency . Furthermore, CYP2D6 genetic polymorphisms have been associated with many treatment failures in several diseases [11,12,13]. CYP2D6 is implicated in tamoxifen activation, a drug administered in hormonal breast cancer therapy, inducing an association between CYP2D6 genotype and treatment response in breast cancer disease [8, 14, 15].
Due to its implication in the susceptibility and treatment of several diseases, and the fact that polymorphic expression of CYP2D6 affects its activity, analysis of CYP2D6 genetic variability is required to develop appropriate therapy for successful treatment. Therefore, CYP2D6 has been investigated in many populations, and the finding showed a substantial variation in allele frequencies among populations [3, 16,17,18]. Indeed, to evaluate CYP2D6 genetic polymorphisms, three alleles were most studied among various populations considering their association with several disease outcomes and treatments [19,20,21]. CYP2D6*3 (rs35742686) is a single-base deletion at exon 5 (A2549del) causing null activity [22, 23]. CYP2D6*4 (rs3892097), a splice site mutation (1846G > A), yields an absence or defective protein in the liver (Sachse et al. 1997). The CYP2D6*10 (rs1065852) 100C/T polymorphism leads to substitution of proline to serine and causes a mRNA splicing defect which produces an IM phenotype . The aim of the present study is to evaluate, for the first time, the distribution of the CYP2D6 gene (CYP2D6*3/*4/*10) in the Moroccan population.
Subjects and blood sample
The current population study enrolled 321 unrelated healthy volunteers recruited during a blood donation campaign. All volunteers from southern Morocco, whom were Arabic, Amazigh, or sub-Saharan Moroccans. All patients received a medical examination during the blood donation campaign and donors with any disease suspicion (diabetes, high arterial blood pressure, etc.) or cancer history were excluded from the study. Peripheral blood was collected based on the World Health Organization criteria (Blood Donor Selection Guidelines, 2012), and written informed consent was obtained from all individuals enrolled in the study. This study was performed under the approval of the Ethics Commission of Cadi Ayyad University Hospital Center (CHU) Mohammed VI, in Marrakech, Morocco.
Genomic DNA was extracted from whole blood using the conventional salting out procedure  with phenol chloroform purification. Extracted genomic DNA was quantified by Qubit Fluorometers (Invitrogen) and the measured values vary 50–74 ng/μl. After PCR amplifications, restriction fragment-length polymorphism analysis (RFLP) was used to genotype CYP2D6 allele analysis. Primers for DNA amplification are given in Table 1. All PCRs were performed in a total volume of 25 μl containing approximately 100 ng of DNA template, 1U of MyTaq of DNA Polymerase enzyme (Bioline, USA), MyTaq Reaction Buffer (0.5 mM NTPs, 1.5 mM MgCl2 with stabilizers and enhancers), along with 200 nM of each appropriate primer [25, 26]. Amplified PCR products were digested with BsaI, BstNI and HphI enzymes (New England Biolabs, USA) for CYP2D6*3, CYP2D6*4 and CYP2D6*10 alleles, respectively. Amplification sizes details and expected digestion results for each SNP are also shown in Table 1.
Allele and genotype frequencies, as well as Hardy–Weinberg equilibrium (HWE), were assessed using SNPStats software . Results are considering significant when P-value is less than 0.05. Pairwise linkage disequilibrium (LD) within the three SNP was performed in terms of Lewontin’s (Dʹ) defined based on normalizing coefficient of linkage disequilibrium D which measures the deviation of haplotype frequencies from expected values based on gene frequencies and informing if alleles are inherited together, and Pearson’s coefficient of correlation (r2) defined as D2 normalized by the product of all allele frequencies. Linkage disequilibrium was assessed using Haploview software . Haplotypic frequencies were assessed using SNPStats software . To compare CYP2D6 allele frequencies in Moroccans with other populations from different ethnic origins, we carried out a qui-square test, a Principal Component Analysis (PCA) and a dendrogram clustering, using R environment .
The allele and genotype frequency distributions of the CYP2D6*3 (A2549del), *4 (G1846A) and *10 (C100T) variants were analyzed in the blood samples of 321 healthy volunteers. Figure 1 presents the alleles in the pattern of the fragments digested for the detection of CYP2D6*3 (A), CYP2D6*4 (B), CYP2D6*10 (C).
According to HW equilibrium analysis (Table 2), all the studied SNPs were in HW equilibrium (P-value > 0.05).
Concerning CYP2D6 genotypes (Table 3), carriers of homozygous wild type for CYP2D6*3 were 76.4%, while 23.6% were heterozygous. The carriers of the wild homozygous genotype of the CYP2D6*4 variant were the most predominant with 80.3%, and the heterozygous genotype represented 18.3%, while the homozygous mutant genotype was 1.4%, while the wild homozygous and heterozygous of the CYP2D6*10 variant were 84.7% and 15.3%, respectively. Minor allele frequencies for CYP2D6*3, CYP2D6*4 and CYP2D6*10 were 11.8%, 10.5% and 7.7%, respectively.
According to our results, the AGC haplotype was the most predominant within our population (77.19%) (Table 4). A strong LD (Dʹ = 0.69; r2 = 0.33; P = 0.000) was found between CYP2D6*4 and CYP2D6*10 SNP, as shown in Fig. 2.
Allele frequencies of the three CYP2D6 polymorphisms were compared with different populations including Mediterraneans, Europeans, Africans, South Americans and Asians (Table 5). The considered studies consisted in the evaluation of CYP2D6 genetic frequencies in a healthy subject (population studies), or investigation the impact of CYP2D6 genotypes on therapy outcomes, and exploring risk susceptibility of CYP2D6 (Association studies/Case–control studies). Results of the three SNPs frequencies comparison showed a significant difference in CYP2D6*3 allele frequency between Moroccans and other ethnic groups, while no difference was observed in CYP2D6*4 and CYP2D6*10 allelic frequencies within the Moroccan population and the majority of European, Mediterranean and African populations (Table 5).
We also performed a PCA and cluster dendrogram to compare CYP2D6 allele frequencies between Moroccans and other populations. However, CYP2D6*3 allele was excluded from PCA analyses due to the significant difference in this allele frequency between Moroccans and other ethnic groups which affect substantially the PCA results. The PCA including data of CYP2D6*4 and CYP2D6*10 alleles revealed genetic proximity between the Moroccan population and Europeans as well as Africans (Fig. 3B). The cluster dendrogram also showed genetic proximity between Moroccans and Africans as well as European populations (Fig. 3A).
The CYP2D6 enzyme is implicated in the metabolism of a wide range of clinically used drugs, such as tamoxifen. Many investigations reported an association of CYP2D6 genetic polymorphisms with susceptibility and response to treatment in many diseases such as autoimmune conditions, cardiovascular diseases and several cancers [52,53,54,55,56,57]. Furthermore, clinical studies reported that CYP2D6 genetic polymorphisms are associated with adverse responses to many drugs such as opioids including codeine, antiarrhythmic drugs and anti-cancer drugs [11,12,13]. Indeed, CYP2D6 is implicated in tamoxifen transformation, a drug usually administrated in breast cancer hormonal therapy . Furthermore, numerous studies reported an association between the CYP2D6 poor metabolizer genotype and recurrences of breast cancer disease with worse event-free survival rates . The role of CYP2D6 includes a large number of medical specialties; indeed, the pharmacogenomics guideline committees have reviewed clinical relevance of CYP2D6, and compiled therapeutic recommendations for more than 48 drugs and developed recommendations based on CYP2D6 genotype/phenotype drugs combinations for 26 drugs (PharmGKB Clinical Guideline Annotations (https://www.pharmgkb.org/guidelineAnnotations). Thus, having information on CYP2D6 genotypes is crucial in deciding the most appropriate therapy for each patient.
Therefore, our study contributes to the determination of the genetic profile of CYP2D6 within the Moroccan population. Overall, the Moroccan population showed a predominance of the wild-type genotype (CYP2D6*3 AA (76.4%); CYP2D6*4 GG (80.3%); CYP2D6*10 CC (84.7%)). These genotypes are responsible for the NM phenotype. For each SNP, about 19% of individuals were carrying an IM phenotype. However, 1.4% of Moroccans had PM phenotype for CYP2D6*4. This latter was investigated in many populations and the results attested to its association with breast cancer susceptibility and treatment [60,61,62]. Haplotype analysis revealed a predominance of AGC haplotype in the Moroccan population (77.19% of cases).
According to our results, an increased CYP2D6*3 (Null allele metabolizer) allelic frequency was observed in Moroccan population compared to others. This allele was found to be associated with acute lymphoblastic leukemia and breast cancer disease [53, 57]. A similar CYP2D6*3 allele frequency was also observed within Brazilians. This proximity might be a consequence of numerous factors, as the fact that Brazilian population have received significant immigration from descendants of original north-African groups, including Berbers , previously stablished in Iberic peninsula (Spain and Portugal) during the large Arabic occupation for about 700 years (711–1492) . Some of them moved directly to Brazil, when settled by Portuguese in 1500 and especially after its independence from Portugal in 1822 , while others made previous migration to Holland and Azoras islands .
The CYP2D6*4 was the most studied null allele within populations. Concerning CYP2D6*4 allelic frequencies, results revealed a significant difference between Moroccan and both Asian and African populations (Ghanaians, Ethiopians), versus a similarity with European and Mediterranean populations (Turkish, Iranian, Finnish, Spanish and Egyptians) (Table 5). This similarity is probably resulting from their closer geographical distance, inducing a certain admixture of populations which boosts a degree of genetic similarity . For CYP2D6*10, a reduced-function allele, frequencies showed a great variability within populations. Indeed, CYP2D6*10 frequencies in Moroccans showed a disparity with European populations, versus a similarity with African, Iranian and Syrian populations. PCA results for CYP2D6*4 and CYP2D6*10 alleles clearly showed genetic proximity between Moroccans and both European and African populations. The dendrogram clustering of populations with such diverse ethnic backgrounds revealed three clusters, the first one represented by the Asians. This cluster is characterized by a high allelic frequency of the CYP2D6*10, and low frequency for CYP2D6*4, and it is clearly distinct from other populations. The second and the third clusters are composed of European and African populations, which are characterized by an average value for the two allele frequencies for the second cluster, and a CYP2D6*4 high allelic frequency and CYP2D6*10 low frequency for the third one. This latter includes Moroccans and other European and African populations (Spanish, Finnish, French, South African).
This study suggests that the Moroccans genetic profile was impacted by historical and demographic events, along the Mediterranean, European, and sub-African populations, leading to its current genetic diversity. Actually, this relevant genetic pool could be interpreted by demographic events, for instance, the influx of Arab populations from the Middle East, Sub-Saharans as well as populations around the Mediterranean area. All these groups contributed to the genetic patrimony of the present-day Moroccan population. . Indeed, the present work and other studies of North African genetic variation, which devote attention to the history of North African and Mediterranean populations, presumed that demographic events contributed to the genetic homogeneity with the nearby regions [68, 69].
Overall, our study revealed that 1.4% of our population carried a PM phenotype for CYP2D6*4 polymorphism. Since CYP2D6 is implicated in the metabolism pathway of many drugs used in several disease treatments, carrying out of CYP2D6*4 polymorphism may affect treatment response. Therefore, pharmacogenetic screening for this gene before any therapy is crucial to avoid treatment failure, hence reduce cost-related issues . Indeed, in many countries, patients take advantage of CYP2D6 screening before treatments . Moroccan population should also consider this recommendation.
The present study attested to the genetic proximity between Moroccan, African and European populations. Furthermore, these results will help to lay a basis for clinical studies, aimed to introduce and optimize a personalized therapy for the Moroccan population.
Availability of data and materials
The datasets supporting the results are included within the article. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available because of privacy or ethical restrictions.
Cytochrome P450 2D6
Principal component analysis
Polymerase chain reaction
Restriction fragment length polymorphism
Ultrarapid metabolizer phenotype
Rendic S, Guengerich FP (2012) Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25:1316–1383. https://doi.org/10.1021/tx300132k
Blackburn HL, Ellsworth DL, Shriver CD, Ellsworth RE (2015) Role of cytochrome P450 genes in breast cancer etiology and treatment : effects on estrogen biosynthesis, metabolism, and response to endocrine therapy. Cancer Causes Control 26:319–332. https://doi.org/10.1007/s10552-014-0519-7
Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J 5:6–13. https://doi.org/10.1038/sj.tpj.6500285
Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336:529–532. https://doi.org/10.1016/0140-6736(90)92086-W
Dai D-P, Geng P-W, Wang S-H, Cai J, Hu L-M, Nie J-J et al (2015) In Vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population. Basic Clin Pharmacol Toxicol 117:39–43. https://doi.org/10.1111/bcpt.12363
Dagostino C, Allegri M, Napolioni V, D’agnelli S, Bignami E, Mutti A et al (2018) CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an italian cohort. Pharmgenom Pers Med 11:179–191. https://doi.org/10.2147/PGPM.S181334
Storelli F, Matthey A, Lenglet S, Thomas A, Desmeules J, Daali Y (2018) Impact of CYP2D6 functional allelic variations on phenoconversion and drug-drug interactions. Clin Pharmacol Ther 104:148–157. https://doi.org/10.1002/cpt.889
Schroth W, Winter S, Mürdter T, Schaeffeler E, Eccles D, Eccles B et al (2017) Improved prediction of endoxifen metabolism by cyp2d6 genotype in breast cancer patients treated with tamoxifen. Front Pharmacol. https://doi.org/10.3389/fphar.2017.00582
Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58:521–590. https://doi.org/10.1124/pr.58.3.6
Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven LJ (2017) Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med 19:69–76. https://doi.org/10.1038/gim.2016.80
Darbar D, Roden DM (2006) Pharmacogenetics of antiarrhythmic therapy. Expert Opin Pharmacother 7:1583–1590. https://doi.org/10.1517/146565184.108.40.2063
Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M et al (2009) Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85:269–272. https://doi.org/10.1038/clpt.2008.218
Leppert W (2011) CYP2D6 in the metabolism of opioids for mild to moderate pain. Pharmacology 87:274–285. https://doi.org/10.1159/000326085
Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV et al (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 85:151–159. https://doi.org/10.1023/B:BREA.0000025406.31193.e8
Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P et al (2006) Polymorphism in the cyp2d6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian tamoxifen trial. J Clin Onscol 24:3708–3709. https://doi.org/10.1200/JCO.2006.06.8072
Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genom 17:93–101. https://doi.org/10.1097/01.fpc.0000239974.69464.f2
Hashemi-Soteh SMB, Sarzare F, Merat F, Salehifar E, Shiran MR (2011) Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3, *4, and *6) within an iranian population (Mazandaran). Genet Test Mol Biomark 15:821–825. https://doi.org/10.1089/gtmb.2011.0033
Pietarinen P, Tornio A, Niemi M (2016) High frequency of CYP2D6 ultrarapid metabolizer genotype in the finnish population. Basic Clin Pharmacol Toxicol 119:291–296. https://doi.org/10.1111/bcpt.12590
Sukasem C, Montri Chamnanphon K, Pechatanan K, Santon N, Puangpetch W, Chantratita W et al (2013) Association of CYP2D6 and CYP2C19 polymorphisms and disease-free survival of Thai post-menopausal breast cancer patients who received adjuvant tamoxifen. Pharmgenom Pers Med 6:37. https://doi.org/10.2147/PGPM.S42330
Lu J, Yang Y, Lu J, Wang Z, He Y, Yan Y et al (2021) Effect of CYP2D6 polymorphisms on plasma concentration and therapeutic effect of risperidone. BMC Psychiatry 21:1–12. https://doi.org/10.1186/S12888-020-03034-9/TABLES/5
Milosavljević F, Bukvić N, Pavlović Z, Miljević Č, Pešić V, Molden E et al (2021) Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis. JAMA Psychiat 78:270–280. https://doi.org/10.1001/JAMAPSYCHIATRY.2020.3643
Dunning AM, Healey CS, Pharoah PDP, Teare MD, Ponder BAJ, Easton DF (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 8:843–854
Khlifi R, Messaoud O, Rebai A, Hamza-Chaffai A (2013) Polymorphisms in the human cytochrome P450 and Arylamine N-Acetyltransferase: susceptibility to head and neck cancers. Biomed Res Int. https://doi.org/10.1155/2013/582768
Miller SA, Dykes DDPH (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215. https://doi.org/10.1093/nar/16.3.1215
Nazir N, Waheed A, Farhat K, Ismail M, Mansoor Q (2016) Frequency of CYP2D6*10 genotypes in Pakistani breast cancer patients taking adjuvant tamoxifen. J Pak Med Assoc 66:1554–1558
Sachse C, Brockmöller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295
Sole X, Guino E, Valls J, Iniesta R, Moreno V (2006) SNPStats: a web tool for the analysis of association studies. Bioinformatics 22:1928–1929. https://doi.org/10.1093/bioinformatics/btl268
Barrett JC, Fry B, Maller J, Daly MJ, Xing J, Witherspoon DJ et al (2005) Haploview: analysis and visualization of LD and haplotype maps HapMap tagSNP transferability in multiple populations: general guidelines. Bioinformatics 21:263–265. https://doi.org/10.1186/1479-5876-11-6710.1093/bioinformatics/bth457
Lê S, Josse J, Husson F, FactoMine R (2008) An R package for multivariate analysis. J Stat Softw 25:1–18
Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ben AS, Chouchane L (2008) Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8:1–12. https://doi.org/10.1186/1471-2407-8-109
Zayed AA, Ahmed AI, Khattab AMT, Mekdad AAH, AbdelAal AG (2015) Paraoxonase 1 and cytochrome P450 polymorphisms in susceptibility to acute organophosphorus poisoning in Egyptians. Neurotoxicology 51:20–26. https://doi.org/10.1016/j.neuro.2015.08.011
Fuselli S, Dupanloup I, Frigato E, Cruciani F, Scozzari R, Moral P et al (2004) Molecular diversity at the CYP2D6 locus in the Mediterranean region. Eur J Hum Genet 12:916–924. https://doi.org/10.1038/sj.ejhg.5201243
Gaedigk A, Coetsee C (2008) The CYP2D6 gene locus in South African coloureds: unique allele distributions, novel alleles and gene arrangements. Eur J Clin Pharmacol 64:465–475. https://doi.org/10.1007/s00228-007-0445-7
Griese EU, Asante-Poku S, Ofori-Adjei D, Mikus G, Eichelbaum M (1999) Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population. Pharmacogenetics 9:715–723. https://doi.org/10.1097/00008571-199912000-00006
Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M (2002) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12:375–383. https://doi.org/10.1097/00008571-200207000-00005
Matimba A, Oluka MN, Ebeshi BU, Sayi J, Bolaji OO, Guantai AN et al (2008) Establishment of a biobank and pharmacogenetics database of African populations. Eur J Hum Genet 16:780–783. https://doi.org/10.1038/ejhg.2008.49
Fernández-Santander A, Gaibar M, Novillo A, Romero-Lorca A, Rubio M, Chicharro LM et al (2013) Relationship between Genotypes Sult1A2 and CYP2D6 and tamoxifen metabolism in breast cancer patients. PLoS ONE. https://doi.org/10.1371/journal.pone.0070183
Albuquerque J, Ribeiro C, Naranjo MEG, Llerena A, Grazina M (2013) Characterization of CYP2D6 genotypes and metabolic profiles in the Portuguese population: pharmacogenetic implications. Per Med 10:709–718. https://doi.org/10.2217/pme.13.56
Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ et al (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193–202. https://doi.org/10.1097/00008571-199706000-00004
Scordo MG, Caputi AP, D’Arrigo C, Fava G, Spina E (2004) Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacol Res 50:195–200. https://doi.org/10.1016/j.phrs.2004.01.004
Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a caucasian population: allele frequencies and phenotypic consequences. Am J Human Genet 60(2):284
Gawronska-Szklarz B, Wójcicki M, Kuprianowicz A, Kedzierska K, Kedzierski M, Górnik W et al (1999) CYP2D6 and GSTM1 genotypes in a polish population. Eur J Clin Pharmacol 55:389–392. https://doi.org/10.1007/s002280050645
Daly AK (2015) Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metab Pers Ther 30:165–174. https://doi.org/10.1515/dmdi-2014-0034
Arvanitidis K, Ragia G, Iordanidou M, Kyriaki S, Xanthi A, Tavridou A et al (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419–426. https://doi.org/10.1111/j.1472-8206.2007.00510.x
Taskin B, Percin FE, Ergun MA (2016) Investigation of CYP2D6 gene polymorphisms in Turkish population. Psychopharmacol Bull 46:67–72
Kouhi H, Hamzeiy H, Barar J, Asadi M, Omidi Y (2009) Frequency of five important CYP2D6 alleles within an Iranian population (Eastern Azerbaijan). Genet Test Mol Biomark 13:665–670. https://doi.org/10.1089/gtmb.2009.0009
da Silva Silveira V, Canalle R, Scrideli CA, de Paula Queiroz RG, Bettiol H, Valera ET et al (2009) Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia. Leuk Res 33:898–901. https://doi.org/10.1016/j.leukres.2008.12.006
Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Gesteira A, Barros F et al (2009) Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics 10:1457–1466. https://doi.org/10.2217/pgs.09.76
Ismail R, Teh L (2001) Genetic polymorphism of CYP2D6: Malaysian Indians have the highest frequency for CYP2D6*4 in Asia. Eur J Clin Pharmacol 57:617–618. https://doi.org/10.1007/s002280100360
Ji L, Pan S, Wu J, Marti-Jaun J, Hersberger M (2002) Genetic polymorphism of CYP2D6 in Chinese mainland. Chin Med J 115:1780–1784
Tateishi T, Chida M, Ariyoshi N, Mizorogi Y, Kamataki T, Kobayashi S (1999) Analysis of the CΥP2D6 gene in relation to dextromethorphan O- demethylation capacity in a Japanese population. Clin Pharmacol Ther 65:570–575. https://doi.org/10.1016/S0009-9236(99)70077-9
Sobti RC, Sharma S, Joshi A, Jindal SK, Janmeja A (2003) CYPIAI and CYP2D6 polymorphism and risk of lung cancer in a North Indian population. Biomarkers 8:415–428. https://doi.org/10.1080/13547500310001619860
Silveira VDS, Canalle R, Scrideli CA, Queiroz RGDP, Tone LG (2010) Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen 51:48–56. https://doi.org/10.1002/em.20510
Luo YP, Chen HC, Khan MA, Chen FZ, Wan XX, Tan B et al (2011) Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumor Biol 32:215–222. https://doi.org/10.1007/s13277-010-0115-8
Rychlik-Sych M, Baranska M, Waszczykowska E, Torzecka JD, Zebrowska A, Skretkowicz J (2013) Genetic polymorphisms of CYP2D6 oxidation in patients with autoimmune bullous diseases. Postep Dermatologii I Alergol 30:211–217. https://doi.org/10.5114/pdia.2013.37030
Bhat MA, Gandhi G (2018) CYP2D6 (C2850T, G1846A, C100T) polymorphisms, haplotypes and MDR analysis in predicting coronary artery disease risk in north-west Indian population: a case-control study. Gene 663:17–24. https://doi.org/10.1016/j.gene.2018.04.008
Elouilamine E, El Akil S, Aznag FZ, Izaabel EH (2020) CYP2D6 gene polymorphisms and breast cancer risk in Moroccan population: a case-control study. Gene Rep 20:100768. https://doi.org/10.1016/j.genrep.2020.100768
Stearns V, Johnson MD, Rae J, Morocho A, Novielli A, Bhargava P et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. CancerSpectrum Knowl Environ 95:1758–1764. https://doi.org/10.1093/jnci/djg108
Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 Genotypes. J Clin Oncol 25:5187–5193. https://doi.org/10.1200/JCO.2007.12.2705
Fernández-Santander A, Del Saz SM, Tejerina Gómez A, Bandrés MF (2012) CYP2D6*4 allele and breast cancer risk: Is there any association? Clin Transl Oncol 14:157–159. https://doi.org/10.1007/s12094-012-0776-4
Levkovich NN, Gorovenko NG, Myasoedov DV (2011) Association of polymorphic G1934A variant (allele*4) of CYP2D6 gene with increased risk of breast cancer development in Ukrainian women 2011:136–139
Surekha D, Sailaja K, Rao DN, Padma T, Raghunadharao D, Vishnupriya S (2010) CYP2D6*4 polymorphisms and breast cancer risk 2:49–55
Lockhart James, Schwartz Stuart B. Early Latin America. A History of colonial Spanish America and Brazil. vol 71. Revue française d’histoire d'outre-mer; 1984
Boone JL, Benco NL (1999) Islamic Settlement in North Africa and the Iberian Peninsula. Annu Rev Anthropol 28:51–71
Nunes RB (2000) Portuguese Migration to Rio de Janeiro, 1822–1850. Americas (Engl Ed) 57:37–61
Chaunu H, Chaunu P (1954) Autour de 1640: politiques et économies atlantiques. Annales 9:44–54. https://doi.org/10.3406/AHESS.1954.2238
Brick C, Atouf O, Bouayad A, Essakalli M (2015) Moroccan study of HLA (-A, -B, -C, -DR, -DQ) polymorphism in 647 unrelated controls: updating data. Mol Cell Probes 29:197–207. https://doi.org/10.1016/j.mcp.2015.04.002
Arnaiz-Villena A, Gomez-Casado E, Martinez-Laso J (2002) Population genetic relationships between Mediterranean populations determined by HLA allele distribution and a historic perspective. Tissue Antigens 60:111–121
Izaabel H, Garchon HJ, Caillat-Zucman S, Beaurain G, Akhayat O, Bach JF et al (1998) HLA class II DNA polymorphism in a Moroccan population from the Souss, Agadir area. Tissue Antigens 51:106–110
Tanner JA, Davies PE, Overall CC, Grima D, Nam J, Dechairo BM (2020) Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective. Pharmacogenomics 21:521–531. https://doi.org/10.2217/PGS-2020-0012
Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM (2020) A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes (Basel) 11:1–23. https://doi.org/10.3390/GENES11111295
We express our gratitude to Mohammed Aghrouch from the Medical Analysis Laboratory at the Regional Hospital Hassan II, Agadir City and El Allali’s Laboratory of Medical Analysis for supplying us with the blood samples. We are also indebted to Pr. António Manuel Dias Brehm for editing and proofreading the article and to Ms Marilyn Irene Dykstra for language editing.
Ethics approval and consent to participate
The study was approved by the Ethical Committee of Cadi Ayyad University Hospital Center (CHU) Mohammed VI, Marrakech, Morocco. (The patient provided written consent).
Consent for publication
Written informed consent was obtained from all patients and controls.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
El Akil, S., Elouilamine, E., Ighid, N. et al. Explore the distribution of (rs35742686, rs3892097 and rs1065852) genetic polymorphisms of cytochrome P4502D6 gene in the Moroccan population. Egypt J Med Hum Genet 23, 153 (2022). https://doi.org/10.1186/s43042-022-00369-8
- CYP2D6 gene
- Moroccan population